BridgeBio Pharma (BBIO) Net Cash Flow (2018 - 2026)

BridgeBio Pharma has disclosed Net Cash Flow across 9 years of filings, most recently posting $309.9 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $309.9 million, up 320.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $339.3 million (up 420.0% YoY), and the FY2025 annual result was -$111.1 million, down 138.51% from the prior year.
• Net Cash Flow came in at $309.9 million for Q1 2026 at BridgeBio Pharma, up from -$73.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $309.9 million in Q1 2026 to a low of -$141.6 million in Q3 2024.
• The 5-year median for Net Cash Flow is $13.1 million (2022), against an average of $28.6 million.
• Across the five-year window, Net Cash Flow jumped 1418.35% in 2023 and plunged 269.76% in 2025, its largest moves.
• BridgeBio Pharma's Net Cash Flow stood at -$68.9 million in 2022, then tumbled by 87.82% to -$129.4 million in 2023, then jumped by 312.79% to $275.4 million in 2024, then slumped by 126.49% to -$73.0 million in 2025, then soared by 524.75% to $309.9 million in 2026.
• The last three Net Cash Flow figures came in at $309.9 million (Q1 2026), -$73.0 million (Q4 2025), and -$106.0 million (Q3 2025), per Business Quant data.